(sub)Massive Controversy: Thrombolytics for Pulmonary Embolism

<p>Cassandra J. Schmitt, PharmD (<a href='https://twitter.com/cjschmitt2'>@cjschmitt2</a>) Identifies the risk stratifications for submassive pulmonary embolism, discusses efficacy and safety outcomes for thrombolytics in submassive pulmonary embolism and selects the ideal candidate to receive thrombolysis for a submassive pulmonary embolism. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>